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Abstract
High-risk (HR) human papillomavirus (HPV) prevalence has been shown to correlate well with
cervical cancer incidence rates. Our study aimed to estimate the prevalence of HR-HPV and
cervical intraepithelial neoplasia (CIN) in China and indirectly inform on the cervical cancer
burden in the country. 30,207 women from 17 population-based studies throughout China were
included. All women received HPV DNA testing (HC2, Qiagen), visual inspection with acetic
acid, and liquid-based cytology. Women positive for any test received colposcopy-directed or 4-
quadrant biopsies. 29,579 women had HR-HPV testing results, of whom 28,761 had biopsy-
confirmed (9019, 31.4%) or assumed (19,742, 68.6%) final diagnosis. Overall crude HR-HPV
prevalence was 17.7%. HR-HPV prevalence was similar in rural and urban areas but showed dips
in different age groups: at age 25–29 years (11.3%) in rural and at age 35–39 (11.3%) in urban
women. In rural and urban women, age-standardized CIN2 prevalence was 1.5% (95%CI: 1.4%–
1.6%) and 0.7% (95%CI: 0.7%–0.8%), and CIN3+ prevalence was 1.2% (95%CI: 1.2%–1.3%)
and 0.6% (95%CI: 0.5%–0.7%), respectively. Prevalence of CIN3+ as a percentage of either all
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women or HR-HPV positive women steadily increased with age, peaking in 45–49 year-old
women. High prevalence of HR-HPV and CIN3+ was detected in both rural and urban China. The
steady rise of CIN3+ up to the age group 45–49 is attributable to lack of lesion removal through
screening. Our findings document the inadequacy of current screening in China while indirectly
raising the possibility that the cervical cancer burden in China is under-reported.
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Introduction
Cervical cancer is the third most common cancer in women with an estimated 530,000 new
cases and 275,000 deaths worldwide per year.1 Corresponding estimates for the People’s
Republic of China are approximately 75,500 new cases (14% of all cervical cancer
worldwide) and 34,000 deaths (12%).1,2 Despite these substantial disease numbers, the age-
standardized cervical cancer incidence rate in China (9.6 per 100,000 women) is lower than
the world average (15.2 per 100,000 women).1,3 However, estimates of cervical cancer
incidence in China derive from incidence-mortality ratios based on cancer registries.1 These
cancer registries include less than two percent of the Chinese population and are located in
urban areas.4 Conversely, 70% of the Chinese population resides in rural areas,5 where 90%
of incident cervical cancer cases are estimated to occur.6
High-risk human papillomavirus (HR-HPV) is the necessary cause of precancerous cervical
intraepithelial neoplasia (CIN) and invasive cervical cancer.7 HR-HPV prevalence has been
found to correlate well with cervical cancer risk in corresponding populations, particularly in
middle-age women.8,9 In addition, the positive correlation between HPV prevalence and the
age-standardized incidence of cervical cancer by subcontinent has been reported recently.10
China’s rapid industrialization and urbanization during the last three decades have coincided
with an epidemic of sexually transmitted disease,11 which may correlate with an increase in
HR-HPV and CIN prevalence as well.
Aiming to determine more realistic rates of HR-HPV, CIN, and cervical cancer prevalence
in China, we performed a pooled analysis on individual data from 10 years of cervical
cancer screening projects, which included 30,207 women from several rural and urban areas
throughout China.
Materials and Methods
From 1999 to 2008, the Cancer Institute/Hospital of the Chinese Academy of Medical
Sciences (CICAMS; Beijing, China), in collaboration with the Cleveland Clinic (Cleveland,
OH, USA), International Agency for Research on Cancer (IARC; Lyon, France) and PATH
(Seattle, WA, USA) screened 30,207 women in population-based, cross-sectional cervical
cancer screening studies in five urban and nine rural areas of China, throughout nine Han
majority provinces. Eligible women were sexually active, not pregnant, had an intact uterus,
and had no history of treatment on the cervix. Recruitments for all the studies were based on
community lists to minimize the selection bias. Most study women had never been screened
for cervical cancer, and none had been screened in the last 5 years. Informed consent was
obtained from all women. The study methodologies have been outlined in detail in the
previously published works.12– 19 The human subjects review boards of CICAMS and
Cleveland Clinic or PATH or IARC approved these studies.
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Information about individual studies is listed in Table 1 and has been published recently in
great detail. 19
Study Procedure
All participants underwent liquid-based cytology (LBC) (SurePath™, BD Diagnostics,
Franklin Lakes, NJ USA or ThinPrep®, Hologic, Bedford, MA, USA), visual inspection
with acetic acid (VIA) and high-risk HPV DNA testing (HC2, Qiagen Inc., Gaithersburg,
MD, USA). All women in SPOCCS I and those positive for any of the three screening tests
in the other studies received biopsy performed using a 2mm bronchoscopy biopsy
instrument. Colposcopy-directed biopsy was used in cases of visible lesions. When study
protocol included random (four-quadrant) punch biopsies (Table 1), biopsies were taken at
positions of two, four, eight, and ten o’clock at the squamocolumnar junction. Details about
study procedure have been published in detail in prior reports.19
HPV Testing
HPV DNA testing was performed using the high-risk probe set of Hybrid Capture 2 (HC2,
Qiagen Inc., Gaithersburg, MD, USA), which detects 13 carcinogenic HPV types (HPV 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). All women received physician-collected
HPV DNA sampling; for primary analyses, HPV DNA positivity was defined according to
the manufacturer’s recommended positive cut-point of 1.0 relative light units per cutoff
(RLU/Co)(≈pg DNA/mL), as previously described.12,20
Verification of Disease Status
In all studies, laboratory personnel performing HC2 were blinded to other test results, and
cytopathologists and histopathologists made diagnoses without knowledge of other test
results. Colposcopists were blinded to the results of all screening tests but were aware one
test was positive, except in SPOCCS I, in which all women received colposcopy regardless
of test positivity.12 In most studies, cytology and biopsy results were read at CICAMS,
although some biopsies were read by local pathologists. Cytology results in 8 studies and
biopsy results in 10 studies were reviewed for quality control by international experts (Table
1). In SPOCCS I and the START studies, all abnormal pathological slides and 10% of the
negatives were reviewed by international clinical experts for re-interpretation.
Comparatively, in SPOCCS III studies, 10%–35% abnormal pathological slides received
international review while in the IARC Yangcheng study, all abnormal cytological slides
and 20% of the negatives were reviewed by international experts.
Data was pooled using a uniform disease-status classification based on histological-
confirmed biopsies. Women without biopsy results, but with negative HR-HPV DNA and
negative or ASC-US at LBC results were considered to be true negatives, based on findings
from SPOCCS I that found only one CIN2 case (1/1511, 0.07% of population) and no
CIN3+ cases among those women.12 Women without biopsy but with negative cytology,
positive HR-HPV DNA, and negative colposcopy were also categorized as negative.
Women were considered as having incomplete data and excluded from the analysis if they
had no biopsy but fell in one of these categories: (1) ASC-US and HR-HPV positive; (2)
LSIL+ (including ASC-H, LSIL, HSIL, AGC, AIS, ADC and SCC); (3) negative cytology,
HR-HPV positive and missing/positive colposcopy; (4) missing cytology.
Statistical Methods
Individual raw data from 17 studies were combined in order to estimate the prevalence of
HR-HPV, different grades of CIN, and cervical cancer. Additionally, overall age-
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standardized prevalence was calculated using the world standard population reported by
Doll and colleagues.21 Crude prevalence is reported when not otherwise specified.
Prevalence stratified by age group (15–24, 25–29, 30–34, 35–39, 40–44, 45–49 and 50–59
years old) were also calculated for HR-HPV and CIN 1, 2, and 3 or worse (CIN3+), and
Cochran–Armitage trend test was used to test the trend of age-stratified prevalence.
Additionally, logistic regression model was used to explore the effects of age and
geographic location on HPV infection status and to explore whether international quality
control affected CIN2+ prevalence, adjusting for age and geographic location. Age-stratified
CIN prevalence in all women and in HR-HPV positive women was restricted to rural
women on account of the relatively low number of urban women in individual age groups
Results
Patient Characteristics
In total, 30,207 women were screened. Figure 1 describes the process by which we obtained
our final sample of 29,579 women with HR-HPV testing results, of which 28,761 had biopsy
confirmed (31.4%) or assumed (68.6%) final diagnosis. Most women (88.4%) in this study
population were from rural areas. The average age of rural women was 40.2 years (SD: 6.2,
range: 17–59 years): most rural women were aged 35–39 (31.3%), 40–44 (28.5%), or 45–49
years (18.8%), though rural women aged 17–24 (1.6%), 25–29 (1.7%), 30–34 (12.2%), and
50–59 years (5.9%) were also included. Among rural women in our study population, almost
all were married (98.7%), with a median number of three pregnancies (range: 0–13; IQR:2–
4) and two live births (range: 0–8; IRQ: 2–3); the mean age of first childbirth was 22.0 years
(standard deviation: 2.81 years).
The remainder of our study population (11.6%,) consisted of urban women. Their average
age was 37.9 years (SD: 9.9, range: 17–59 years); 9.2% of urban women aged 17–24 years;
16.1% 25–29; 15.9% 30–34; 14.6% 35–39; 15.3% 40–44; 13.2% 45–49; and 15.7% aged 50
or older. The majority of urban women were married (89.7%), with a median of two
pregnancies (range: 0–11, IQR:1–3) and one live birth (range: 0–5, IQR:1-1). The mean age
at first childbirth among urban women was 26.0 years (standard deviation 3.28 years).
Sexual behavior differed by geographic location: rural women had a younger mean age of
sexual debut (20.8 years, SD: 2.2 years) compared to urban women (23.7 years, SD: 3.1
years). Similarly, 22.1% of rural women reported having had two or more lifetime sexual
partners compared to 15.7% of urban women. The mean age and sexual debut age of women
excluded from the analysis was 39.1 (SD: 7.1) and 19.5 (SD: 2.6). The excluded population
had the same median number of pregnancies and live births as included women.
High risk (HR) HPV DNA Prevalence by Geographic Location
Overall crude and age-standardized HR-HPV prevalence in our study population were
17.7% and 16.8%, respectively (Table 2). When stratified by geographic location, crude and
age-standardized HR-HPV prevalence was 18.0% and 16.3% (95%CI: 16.0%–16.6%) in
rural women, respectively, and 15.2% and 16.0% (95%CI: 15.7%–16.3%) in urban women,
respectively (Table 2). When stratified by age, crude HR-HPV prevalence in rural women
declined from 16.2% in 15–24 year-old women to 11.3% in 25–29 year-old women before
increasing in women aged 35–39 years (18.6%) and then remaining stable (Ztrend=5.079,
Ptrend<0.0001) (Figure 2). Among urban women, the crude HR-HPV prevalence declined
from 18.7% in 15–24 year-old women to 11.3% in 35–39 year-old women before increasing
again to approximately 16.0% in women aged 40 or older (Ztrend=−0.986, Ptrend=0.324)
(Figure 2). Logistic regression analysis also showed that, compared with the women aged
15–24 years, those aged 25–29 (OR=0.769, OR 95%CI: 0.593–0.999) and 30–34 years
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(OR=0.752, OR 95%CI: 0.609–0.929) had lower HPV prevalence, while women older than
35 years had a higher HPV prevalence comparable to that of women aged 15–24 years. This
analysis also showed HPV prevalence was lower in urban areas than in rural areas
(OR=0.870, OR 95%CI=0.785–0.965).
CIN1,CIN2 and CIN3+ Prevalence
Overall crude and age-standardized prevalence was 3.4% and 3.1% (95%CI: 2.9%–3.2%),
respectively, for CIN1, 1.5% and 1.3% (95%CI: 1.2%–1.3%), respectively, for CIN2, and
1.6% and 1.2% (95%CI: 1.1%–1.2%), respectively, for CIN3+ (Table 2). Forty-nine women
(48 rural, one urban) were diagnosed with cervical cancer (Table 2). Among rural women
age-standardized prevalence in rural women was 3.4% (95%CI: 3.2%–3.5%) for CIN1,
1.5% (95%CI: 1.4%–1.6%) for CIN2, and 1.2% (95%CI:1.2%–1.3%) for CIN 3+. Lower
age-standardized prevalence rates of CIN1 (2.1%; 95% CI: 2.0%–2.2%), CIN2 (0.7%; 95%
CI: 0.7%–0.8%) and CIN3+ (0.6%; 95% CI: 0.5%–0.7%) were found in urban women
(Table 2).
Age-stratified prevalence of CIN1, 2, and 3+ in rural women is shown in Figure 3. CIN1
prevalence was lowest in women younger than age 35 but increased in 35–39 year-old
women (3.9%) and remained constant afterwards (Ztrend=0.710, Ptrend=0.478) (Figure 3).
CIN2 prevalence in rural women was rather constant, with the highest level (1.9%) in 40–44
year-old women (Ztrend=1.350, Ptrend=0.177). CIN3+ prevalence steadily increased up to
2.5% in 45–49 year-old women before slightly diminishing to 1.7% in women aged 50–59
years (Ztrend=5.803, Ptrend<0.0001) (Figure 3).
After adjusting for age and geographic location, logistic regression analysis showed CIN2+
prevalence was lower in studies that had histological slides reviewed by international
experts (2.8%, 437/15697) compared to those that had no international re-interpretation
(3.6%, 476/13064) (OR=0.758, OR 95%CI: 0.663–0.867).
CIN1, CIN2, and CIN3+ Prevalence in HR-HPV positive women
Overall, 4,500 rural women and 357 urban women were positive for HR-HPV (Table 2).
Within the subset of rural women, overall crude prevalence was 16.3% for CIN1, 8.7% for
CIN2, and 9.8% for CIN3+, while the age-standardized prevalence was 19.1% (95%CI:
18.8%–19.4%) for CIN1, 8.9% (95%CI: 8.7%–9.1%) for CIN2, and 7.6% (95%CI: 7.4%–
7.9%) for CIN3+ (Table 2). Comparatively, HR-HPV positive urban women had lower
crude and age-standardized CIN1, CIN2, and CIN3+ prevalence (Table 2).
Age-stratified prevalence of CIN1, 2, and 3+ among HR-HPV positive women was, as
before, restricted to the subpopulation of rural women (Figure 4). CIN1 prevalence among
HR-HPV positive rural women declined with age from 23.8% in 15–29 year-old women to
13.0% in 50–59 year-old women (Ztrend=−2.713, Ptrend=0.007). CIN2 prevalence was
approximately constant with age and ranged between 8.1% in women aged 30–34 years and
50–59 years and 9.6% in 40–44 year-old women (Ztrend=0.046, Ptrend=0.964). CIN3+
prevalence in HR-HPV positive rural women steadily increased with age up to 12.8% in 45–
49 year-old women and then slightly declined (Ztrend=4.719, P<0.0001) (Figure 4).
The CIN2+ prevalence among HR-HPV positive women was slightly higher in studies in
which histological slides were reviewed by international experts (18.8%, 420/2240)
compared to those that did not have international experts re-interpret histology (17.6%,
460/2617), but statistical difference was not shown (OR=1.073, OR 95%CI: 0.922–1.248).
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This pooled analysis is the largest study ever conducted on the prevalence of HR-HPV
infection and CIN in China, with seventeen study sites in nine Chinese provinces
represented. Data were collected in several communities throughout the country and our
study population was composed predominantly of rural women, in agreement with the
general female population in the country.5
Compared to the prevalence of HPV (9.9%) in Beijing,22 which is one of the seven cancer
registries in China included in Cancer Incidence in Five Continents, the age-standardized
HR-HPV prevalence in our study population (16.8%) was much higher, but similar to that in
Southern India23 and higher than that in many other low- and intermediate resource
countries in Asia (including Thailand, Nepal, Vietnam, and Pakistan).24–26 Only in
Mongolia27 was substantially higher HR-HPV prevalence found. When stratified by age and
geographic location, age-specific HR-HPV prevalence curves showed a transient decline in
rural women aged 25–29 years and 35–39 years in urban women. Bimodal distribution of
HPV prevalence is consistent with prior studies from Latin America28 and Asia29 but
different from the flat age-specific HPV prevalence curves observed in other studies from
Asia.23 Our findings are also at variance with those from recent meta-analyses which
showed that the HR-HPV curve in Asia decreased steadily with increasing women’s
age. 24,30
The difference in age-specific HR-HPV prevalence by area of living may depend on age-
related variations in sexual and reproductive behavior between urban and rural Chinese
women. The period of childbearing in China and elsewhere tends be accompanied by
stronger family ties and fewer extra-marital sexual affairs. Earlier dip in HR-HPV
prevalence in rural women may therefore be explained by the fact that age at first
intercourse and first birth were three and four years earlier, respectively, for rural women
compared to urban women. Furthermore, more rural women reported having two or more
lifetime sexual partners (22%) than urban women (16%). Although this study did not
include information on changes husband’s sexual behavior after attaining final family size,
new husband’s extramarital sexual relationships may also contribute to a second rise of HR-
HPV prevalence in married women.
In agreement with the relatively elevated prevalence of HR-HPV infection, our study,
showed also high prevalence of every grade of CIN among Chinese women. Nearly 2% of
women in our study harbored CIN3+, an elevated prevalence that is most probably
explained by the inadequacy of past and current cervical cancer screening practices in
China, particularly among rural women. Of note, the assessment of age-stratified CIN
prevalence in our study had to be restricted to rural women not only due to the relatively low
number of urban women in individual age groups but also due to comparability problems
between studies. In fact, studies in rural areas tended to have more comprehensive
histological assessment for the presence of CIN than did those from urban areas.
The prevalence of CIN among HR-HPV positive women is of special interest as these
lesions may eventually progress to cervical cancer. Age-stratified CIN1 prevalence among
HR-HPV positive rural women steadily declined until age 40–44 years, indicating that CIN1
is an early correlate of virus acquisition, particularly among younger women.31 Conversely,
similar to previous research,32 in our inadequately screened population, the prevalence of
CIN3+ increased with age up until age 45–49 years. In addition to the fact that the lack of
lesion removal through screening may contribute to this pattern, a biological interpretation
for the increasing CIN3+ prevalence is the natural effect of aging. More specifically, recent
research33 has shown a strong menopause-related effect on cervical cancer risk, with an
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increasing risk of cancer following incident infection but decreasing overall prevalence of
new CIN3+ since CIN3 cases (though not cervical cancer) arise less frequently among older
women compared to younger women. As expected, the prevalence of CIN2 among HR-HPV
positive women shows an age-related pattern intermediate between those of CIN 1 and
CIN3+ supporting prior evidence of the heterogeneity of CIN2 and the concomitant
difficulty of distinguishing CIN 2 lesions from lower or higher grades of CIN.34
Combined prevalence of CIN2 and CIN3+ in Chinese women (approximately 3%) was
higher than the corresponding prevalence in other Asian countries, where it ranged between
0.5% in Thailand25 and 1.6% in Mongolia.27 In addition, the maximal prevalence of
combined CIN 2 and CIN3+ was observed Chinese women older than 40–44 years, which
was later than the maximal prevalence of CIN2+ in a recent meta-analysis of Asian
women31 and a previous study in Hong Kong.29
The high prevalence of CIN2+ in middle age Chinese women should inform cervical cancer
screening policies in China and other low- and intermediate-resource countries. Current
cervical cancer screening recommendations are that women between the ages of 35 and 40
years be screened at least once with cervical cytology, HPV DNA testing, or visual
inspection with acetic acid (in low-resource settings).35 However, our findings show that
Chinese women aged 40 years or older should also be screened as they harbor a substantial
proportion of precancerous cervical lesions that accumulated over time and may still be the
target of life-saving treatments. Indeed, a recent population-based study from rural Nigeria
showed that the positive predictive value of an HR-HPV positive test was greater in women
aged 50 years or older than in women younger than age 30 and not significantly lower than
in 30–49 year-old women.36
About 40% of women with undiagnosed CIN3 have been shown to develop cervical
cancer.37 Our present findings indirectly raise, therefore, the possibility that cervical cancer
incidence in China may be higher than currently estimated (9.6 per 100,000 women1).
Chinese cancer registries on which nationwide cancer incidence are estimated include only
2% of Chinese population and are located in five urban settings.1,3 Residents of these five
cities have annual incomes that range from 1.3 to 3 times higher than the national Chinese
average,4,5 suggesting that the population composition of Chinese cancer registries may not
be representative of the whole country. Furthermore, some comprehensive data on cervical
cancer mortality4 showed that in rural China cervical cancer mortality rates were higher than
those for any other cancer in women.38 Although our present study population is more
representative of the Chinese population than are the national cancer registry areas, and we
carefully evaluated a majority of participating women for HR-HPV and CIN prevalence,
residual underestimation CIN3+ prevalence is likely to be present also in our study for
different reasons. Firstly, a not negligible fraction of HR-HPV positive women who did not
receive a cervical biopsy were excluded from our present analysis. Secondly, under-
ascertainment of CIN2+ may have occurred in our study sites (mainly urban sites) where 4-
quadrant biopsies were not performed.39
Our present pooled analysis has several strengths. It includes 17 population-based studies all
conducted by CICAMS that utilized similarly trained staff and similar screening protocols.
Moreover, cytology results and histology results in all studies were verified by senior
cytopathologists at CICAMS and/or international experts. Nearly half of final diagnoses
derived from biopsy results, and four-quadrant punch biopsies were used in selected sites
when no suspicious lesion was observed in colposcopy.18 Finally, reliance on three negative
screening tests to classify a woman as negative should have allowed good sensitivity level.40
Because the CIN prevalence in our study was relatively higher than that of other Asian
countries, we evaluated the potential effect of international reviewing of histology to verify
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whether over-diagnosis of CIN2+ from Chinese pathologists existed. This analysis showed
that CIN2+ prevalence was lower in studies that had international review (2.8%, 437/15697)
compared to those that had not (3.6%, 476/13064) (OR=0.758, OR 95%CI: 0.663–0.867).
However, once the analysis was limited to HPV-positive women, no statistical difference
was shown between CIN2+ prevalence in internationally reviewed studies (18.8%,
420/2240) and that of non-internationally reviewed studies (17.6%, 460/2617) (OR=1.073,
OR 95%CI: 0.922–1.248). Considering that 96.4% of CIN2+ lesions (880/913) occurred in
HPV-positive women, the statistical difference revealed by logistic regression modeling in
CIN2+ prevalence of all women was probably secondary to the large sample size. Moreover,
10 of 17 studies had been reviewed by international experts, so the over-diagnosis was very
limited. A limitation to our study is the relatively small size of urban women that limited our
possibility to compare CIN prevalence by area of living in individual age groups.
In conclusion, our findings on high prevalence of HR-HPV infection and CIN2+ suggest
that the cervical cancer burden in China is heavy and comprehensive screening and HPV
immunization efforts are warranted.
Novelty/Impact
This largest population-based study in China revealed a remarkably high prevalence of
HR-HPV infection and every grade of CIN among Chinese women, indicating China
could face a significantly increased cervical cancer burden if comprehensive vaccination
and screening programs are not implemented in the vast population in time. The bimodal
distribution of HPV prevalence by age will have significant programmatic implications
for cervical cancer screening policies in China as well as other similar countries.
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CICAMS Cancer Institute/Hospital of the Chinese Academy of Medical Sciences
CIN cervical intraepithelial neoplasia
CIN1 cervical intraepithelial neoplasia grade 1
CIN2 cervical intraepithelial neoplasia grade 2
CIN2+ cervical intraepithelial neoplasia grade 2 or worse
CIN3 cervical intraepithelial neoplasia grade 3
CIN3+ cervical intraepithelial neoplasia grade 3 or worse
ECC endocervical curettage
HC2 digene HPV HC2 DNA test
HR-HPV high-risk human papillomavirus
HSIL high-grade squamous intraepithelial lesion
IARC International Agency for Research on Cancer
LBC liquid-based cytology
LSIL low-grade squamous intraepithelial lesion
LSIL+ low-grade squamous intraepithelial lesion or worse
PATH Program for Appropriate Technology in Health
SCC squamous cell carcinoma
SPOCCS Shanxi Province Cervical Cancer Screening Study
START Screening Technologies to Advance Rapid Testing Project
VIA visual inspection with acetic acid
VILI visual inspection with Lugol’s iodine
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Flow chart of inclusion and exclusion criteria of the study sample
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Prevalence of high-risk HPV DNA stratified by residence
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Prevalence of CIN1, CIN2 and CIN3+ stratified by age group among rural women
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Prevalence of CIN1, CIN2 and CIN3+ in rural women with high-risk HPV stratified by age
group
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